Note 12 - Restructuring

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

12

.

Restructuring

During the

third

quarter of

2017,

the Company’s management committed to a plan to terminate various government grants that were acquired as part of the acquisition of Immunetics. As a result, the Company terminated

15

employees during the

fourth

quarter of

2017

and recorded restructuring charges of

$169,000

in research and development expense and

$13,000

in general and administrative expense.

The following table provides a rollforward of the liability balance for this restructuring. Accrued restructuring costs at

December 31, 2017

and

September 30, 2018

were included in accrued liabilities in the accompanying balance sheet.

(in thousands)	Severance
Balance at December 31, 2017	$	74
Payments		(70	)
Balance at September 30, 2018	$	4